Legend Biotech: China's Nmpa Approves Ciltacabtagene Autoleucel for Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma
傳奇生物:中國國藥準字批准Ciltacabtagene Autoleucel用於治療成人復發或難治性多發性骨髓瘤患者
Legend Biotech: China's Nmpa Approves Ciltacabtagene Autoleucel for Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma
傳奇生物:中國國藥準字批准Ciltacabtagene Autoleucel用於治療成人復發或難治性多發性骨髓瘤患者
譯文內容由第三人軟體翻譯。